[[-2]proPSA improves prediction of repeat prostate biopsy results

Axel Semjonow¹, Reemt Hinkelammert¹, Thomas Köpke¹, Mahmoud Abbas², Elke Eltze³, Frank Oberpenning⁴

¹Prostate Center, University Hospital Münster Dept. of Urology. ²Gerhard-Domagk-Institute of Pathology. ³Institute for Pathology, Saarbrücken-Rastpfuhl. ⁴Dept. of Urology, St. Agnes Hospital Bocholt. Germany.

OBJECTIVES

The use of prostate specific antigen (tPSA) for the detection of prostate cancer (PCa) is being criticized because of a relatively low specificity. In repeat prostate biopsies the predictive value of tPSA is very low. The clinical performance of a molecular isoform of free PSA (fPSA), [-2]proPSA, for the detection of PCa in initial versus repeat prostate biopsies was evaluated.

METHODS

A total of 377 patients with tPSA values between 1.6 – 8.0 ng/mL (median 5.07, mean 5.01 ng/ml WHO-calibrated Hybritech Access) underwent ≥10 core biopsies. 209 pts. underwent their first biopsy session (tPSA 1.6 - 8.0 ng/mL, median 5.0, mean 5.1), 191 pts. underwent repeat biopsies (tPSA 1.6 - 8.0 ng/mL, median 5.48 mean 5.32). Prior to biopsy, serum samples were prepared within 3 hours from blood draw and frozen at -75°C immediately [Semjonow et al. Clin Biochem 2010]. The serum concentrations of tPSA, fPSA, and [-2]proPSA were measured with the automated Beckman Coulter immunoassays on the Access2 instrument.

RESULTS

Evaluation of the two cohorts using area under ROC curve (AUC) analysis showed the following results:

First biopsy cohort: [-2]proPSA/fPSA (AUC=0.72) provided significantly (p<0.005) better clinical performance relative to tPSA (AUC=0.56) but was not significantly better than f/tPSA (AUC=0.66) in predicting PCa.

Repeat biopsy cohort: [-2]proPSA/fPSA (AUC=0.73) provided significantly better prediction of biopsy outcome relative to f/tPSA (AUC= 0.60) or tPSA (AUC 0.51), differences between AUCs p<0.001. Difference between f/tPSA and tPSA p<0.03.

The diagnostic accuracy of [-2]proPSA/fPSA improves with increasing prostate volume.

CONCLUSIONS

[-2]proPSA/fPSA shows a superior clinical performance in detecting PCa in the tPSA range of 1.6 - 8.0 ng/mL (i.e. 2 – 10 ng/mL in traditional calibration) as compared to tPSA or f/tPSA. In pts. undergoing repeat prostate biopsy, [-2]proPSA/fPSA shows the highest AUC outperforming all other parameters investigated statistically significant. Performance of [-2]proPSA/fPSA increases with increasing prostate volume, thus possibly providing important information for the group of pts. in which a decision concerning repeat biopsies is most difficult.

REFERENCES

- Jansen et al. Prostate-Specific Antigen (PSA) isoform p2PSA in Combination with Total PSA and Free PSA Improves Diagnostic Accuracy in Prostate Cancer Detection. European Urology 2010; 57: 921-27